TickerFacts.

Zeo ScientifiX, Inc. (ZEOX): Total Liabilities

Annual figures by period end, from SEC filings.

$2.95M
As of 2025-10-31
$3.17M
As of 2026-04-30
-11.9%
3-year compound annual growth
+1.6%
5-year compound annual growth
+35.7%
10-year compound annual growth
$4.60M2014-10-31: $63.2K2015-10-31: $139.7K2016-10-31: $853.0K2020-10-31: $2.73M2021-10-31: $4.60M2022-10-31: $4.31M2023-10-31: $4.02M2024-10-31: $3.30M2025-10-31: $2.95M$2.95M
2014-10-31 Total Liabilities (USD) 2025-10-31
Period endedTotal LiabilitiesChange YoYSource filing
2025-10-31$2.95M-10.5%2026-01-29, Balance as of period end
2024-10-31$3.30M-18.1%2026-01-29, Balance as of period end
2023-10-31$4.02M-6.7%2025-01-29, Balance as of period end
2022-10-31$4.31M-6.2%2024-01-29, Balance as of period end
2021-10-31$4.60M+68.7%2023-02-14, Balance as of period end
2020-10-31$2.73Mn/a2022-02-14, Balance as of period end
No annual figure between 2016-10-31 and 2020-10-31.
2016-10-31$853.0K+510.4%2017-07-07, Balance as of period end
2015-10-31$139.7K+121.1%2017-07-07, Balance as of period end
2014-10-31$63.2Kn/a2016-06-22, Balance as of period end

Total Liabilities at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedTotal LiabilitiesChange YoY
Zeo ScientifiX, Inc. (ZEOX)2025-10-31$2.95M-10.5%
DBV Technologies S.A. (DBVT)2025-12-31$64.95M+69.7%
Prime Medicine, Inc. (PRME)2025-12-31$221.87M+53.7%
Ocugen, Inc. (OCGN)2025-12-31$55.68M+5.4%
CG Oncology, Inc. (CGON)2025-12-31$38.99M+82.0%
CRISPR Therapeutics AG (CRSP)2025-12-31$343.43M+10.8%
Surrozen, Inc. (SRZN)2025-12-31$286.49M+310.2%
Dyadic International Inc (DYAI)2025-12-31$8.71M+16.8%
Curis Inc (CRIS)2025-12-31$14.50M-69.3%

Compare ZEOX, DBVT, PRME, OCGN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗